• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK Archive

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view current FDA-TRACK performance measures and projects view the Active Index

Filter








Results

Number of results: 35

ItemProgramOfficeFY
Completed
Strategic PlanStrategic Goal/Area
1Number of OCET-coordinated meetings regarding CT and ET issues with Centers in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
2Number of external meetings (hosted by CDC, NIH, industry, and sponsors) attended by OCET to communicate agency policy on CT and ET in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
3Number of meetings to discuss Pre-Emergency Use Authorization (EUA) development in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
4Number of documents reviewed for CT and ET policy development in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
5Total number of meeting requests received through MCM.gov in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
6Number of meetings FDA attends with sponsors who requested a meeting through MCM.gov in the monthOCSOffice of Counterterrorism and Emerging Threats2011N/AN/A
7Implement MCM Initiative (MCMi)OCSOffice of Counterterrorism and Emerging Threats2012N/AN/A
8Strategic Science and Innovation PlanOCSOffice of the Chief Scientist2011N/AN/A
9Tuberculosis InitiativeOCSOffice of Regulatory Science and Innovation2011N/AN/A
10Tuberculosis Frozen Trial RepositoryOCSOffice of Regulatory Science and Innovation2013N/AN/A
11Neglected/Tropical Disease InitiativeOCSOffice of Regulatory Science and Innovation2011N/AN/A
12Modernize Toxicology TestingOCSOffice of Regulatory Science and Innovation2011N/AN/A
13Improving the Efficiency of Clinical TrialsOCSOffice of Regulatory Science and Innovation2011N/AN/A
14Health Resources and Services Administration (HRSA) Patient Safety and Clinical Pharmacy Services CollaborativeOCSOffice of Women's Health2011N/AN/A
15Video NovellaOCSOffice of Women's Health2012N/AN/A
16Number of OWH staff attending venues and partner activities where women’s information is provided in the monthOCSOffice of Women's Health2014N/AN/A
17Total number of electronic OWH distributions in English and other foreign languages in the quarterOCSOffice of Women's Health2014N/AN/A
18Total number of physical OWH distributions in English and other foreign languages in the quarterOCSOffice of Women's Health2014N/AN/A
19Total number of OWH partner distributions in the quarterOCSOffice of Women's Health2014N/AN/A
20Cumulative number of subscribers to OWH email lists and social media outlets at the end of the monthOCSOffice of Women's Health2014N/AN/A
21Cumulative number of abstracts, posters, presentations or publications by OWH staff accepted in the monthOCSOffice of Women's Health2014N/AN/A
22Modernizing ToxicologyOCSOffice of the Chief Scientist2013N/AN/A
23Centers of Excellence in Regulatory Science and Innovation (CERSI)OCSOffice of Regulatory Science and Innovation2015OCS Strategic Priorities FY 2014Support mission critical targeted research and raise the profile of regulatory science
24Broad Agency Announcement (BAA)OCSOffice of Regulatory Science and Innovation2013N/AN/A
25FDA Nanotechnology Regulatory Science ProgramOCSOffice of Regulatory Science and Innovation2013N/AN/A
26Number of Departmental meetings in the month related to HHS Health Disparities Plan ImplementationOCSOffice of Minority Health2013N/AN/A
27Number of HHS and FDA working groups impacting health literacy led or participated in during the monthOCSOffice of Minority Health2013N/AN/A
28Number of Departmental meetings in the month related to ACA implementationACAOffice of Minority Health2013N/AN/A
29Cumulative number of visits to new FDA minority health webpage in the monthOCSOffice of Minority Health2013N/AN/A
30Number of external FDA stakeholder meetings in the monthOCSOffice of Minority Health2013N/AN/A
31Strengthen FDA capacity to address minority health and health disparities across the AgencyACAOffice of Minority Health2013N/AN/A
32Strengthen Regulatory Science/Health Disparities Research InitiativesACAOffice of Minority Health2013N/AN/A
33Strengthening FDA Outreach and Communication Programs to Minority Health Care Providers and PatientsOCSOffice of Minority Health2014OCS Strategic Priorities FY 2014Support mission critical targeted research and raise the profile of regulatory science
34The Science of Sex and Gender in Human Health Modules III and IVOCSOffice of Women's Health2015OCS Strategic Priorities FY 2014Support an environment of scientific excellence, learning and integrity
35Medical Countermeasure DevicesMEDICAL COUNTERMEASURES INITIATIVEN/A2015OCS Strategic Priorities FY 2014Ensure that our nation is prepared for threats of emerging infectious diseases, pandemics and terrorism

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.